Psychiatry

This month in review focuses on innovative therapies in psychiatry, including MM120 for anxiety and ammoxetine for depression, as well as providing safety insights.

Both organizations defend the use of Tylenol during pregnancy, citing “rigorous” and “reputable” research suggesting it does not cause autism in children.

A phase 2 trial demonstrated the effectiveness, safety, and tolerability of ammoxetine (40 and 60 mg) in patients with major depressive disorder.

Both ACOG and AAP have released statements disagreeing with the FDA label change for acetaminophen to reflect autism risk in children if used during pregnancy.

The Agency initiated an acetaminophen label change to reflect evidence of potential harms in pregnant women and an approval of leucovorin for CFD.

EADV 2025 findings show patients with atopic eczema face greater risks of depression, anxiety, sleep disorders, and stigmatization.

A study suggests associations between opioids during pregnancy and neurodevelopmental disorders are mainly due to confounding factors, not causal effects.

MDMA’s CRL, now available to the public, cites gaps in safety data, selection bias, and limited durability.

Fava discusses promising phase 2b trial findings: a single 100 μg dose of MM120 rapidly reduces GAD symptoms by day 2, with benefits lasting 12 weeks.

A phase 2b trial finds a single 100 μg dose of MM120 reduced GAD symptoms with benefits lasting 12 weeks, highlighting the promise of psychedelic therapy.

A 30-week trial found weekly semaglutide reduced HbA1c while improving physical quality of life in patients on antipsychotics.

Check out the top 5 psychiatry headlines in August 2025, including the fast-track designation of NRX-100 for suicidal ideation.

The 9-week intervention targeting positive psychological wellbeing in IBS was feasible, well-accepted, and linked to improvements in IBS-related outcomes.

Up to half of psoriasis patients report significant psychiatric symptoms, highlighting the importance of routine screening in practice.

Any alcohol intake was linked to a greater risk of liver mortality, but healthy diet and physical activity lowered this risk across all drinking patterns.

Phase 2 data shows meaning-centered psychotherapy may strengthen psilocybin-assisted therapy for depression in patients with cancer and MDD.

In a study, ADHD treatments were linked to reduced suicidal behavior, substance misuse, transport accidents, and criminality, but not accidental injuries.

Stay updated with the latest healthcare breakthroughs, including FDA news and new cardiology research, in this week's essential news roundup.

In a new study, esketamine nasal spray improved anhedonia in treatment-resistant unipolar and bipolar depression, independent of general symptom changes.

A recent study shows combined treatment increases total and N3 sleep in just 3 days for patients with comorbid insomnia and depression.

Single-dose psychedelic therapy (RE104 30 mg) shows rapid improvements in postpartum depression, offering a potential alternative to slow-acting therapies.

Phase 4 data reveal esketamine outperforms standard antidepressants in reducing insomnia and boosting next-day well-being in patients with TRD.

FDA grants Fast Track to NRX-100, the first preservative-free IV ketamine, for treating suicidal ideation in depression.

Co-locating ID screening in an inpatient SUD program resulted in timely identification of and linkage to care for viral hepatitis and latent tuberculosis.

Kratom poses serious addiction risks despite its natural appeal, misleading many into believing it's a safe alternative for pain and withdrawal relief.